StemCell Therapy

Vident Investment Advisory LLC bought a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,197 shares of the biotechnology companys stock, valued at approximately $284,000.

A number of other hedge funds also recently modified their holdings of SRPT. Evolution Wealth Advisors LLC boosted its stake in Sarepta Therapeutics by 1,143.8% in the fourth quarter. Evolution Wealth Advisors LLC now owns 199 shares of the biotechnology companys stock valued at $26,000 after acquiring an additional 183 shares during the period. San Francisco Sentry Investment Group CA acquired a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $34,000. Lighthouse Financial Advisors Inc. acquired a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $42,000. Advisory Services Network LLC boosted its stake in Sarepta Therapeutics by 531.4% in the fourth quarter. Advisory Services Network LLC now owns 322 shares of the biotechnology companys stock valued at $42,000 after acquiring an additional 271 shares during the period. Finally, Tower Research Capital LLC TRC acquired a new position in Sarepta Therapeutics in the third quarter valued at approximately $47,000. Institutional investors own 97.11% of the companys stock.

SRPT has been the subject of a number of research reports. HC Wainwright lifted their target price on Sarepta Therapeutics from $160.00 to $260.00 in a research note on Friday, December 13th. JMP Securities decreased their target price on Sarepta Therapeutics from $280.00 to $217.00 and set an outperform rating for the company in a research note on Thursday, February 27th. Oppenheimer reiterated a hold rating on shares of Sarepta Therapeutics in a research report on Monday, December 30th. Cowen reiterated a buy rating and set a $213.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, January 14th. Finally, Royal Bank of Canada reduced their price objective on Sarepta Therapeutics from $215.00 to $200.00 and set an outperform rating for the company in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a hold rating, twenty-four have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $193.95.

SRPT traded down $9.97 during trading on Monday, reaching $107.13. The stock had a trading volume of 42,503 shares, compared to its average volume of 733,097. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -11.21 and a beta of 2.08. The company has a quick ratio of 4.90, a current ratio of 5.55 and a debt-to-equity ratio of 0.89. Sarepta Therapeutics Inc has a 1-year low of $72.05 and a 1-year high of $158.80. The stock has a 50 day moving average of $119.68 and a two-hundred day moving average of $105.71.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing analysts consensus estimates of ($1.86) by ($1.30). The firm had revenue of $100.11 million during the quarter, compared to analyst estimates of $100.10 million. Sarepta Therapeutics had a negative return on equity of 67.13% and a negative net margin of 187.77%. During the same quarter last year, the company earned ($2.05) earnings per share. On average, research analysts forecast that Sarepta Therapeutics Inc will post -8.22 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Further Reading: Balance Sheet

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Vident Investment Advisory LLC Buys Shares of 2,197 Sarepta Therapeutics Inc (NASDAQ:SRPT) - Redmond Register

This entry was posted on March 10, 2020 at 7:45 pm and is filed under Genetic medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |